CDC: Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported
Researchers determined there were 21 cases of anaphylaxis after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States.
Researchers determined there were 21 cases of anaphylaxis after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States.
Researchers analyzed how substance use disorder affected the risk of hospitalization, complications and mortality among adult patients who were diagnosed with having a COVID-19 infection.
When the pandemic first reached Boston in March 2020, Massachusetts General Hospital responded by redeploying advanced practice providers, including nurse practitioners and physician assistants.
New data released by the FDA suggests that Pfizer’s two-dose COVID-19 vaccine works well protecting recipients against COVID-19.
Study authors evaluated whether use of aspirin in hospitalized patients with COVID-19 was associated with reduced risk of mechanical ventilation, reduced risk for intensive care unit admission, and in-hospital mortality.
Mask wearing is top CDC recommendation to help stop the spread of COVID-19.
Small practices and rural clinics anticipate challenges storing and administering COVID-19 vaccines.
Emergency use authorization was issued for baricitinib in combination with remdesivir for hospitalized patients with COVID-19.
Support staff in health care settings have higher COVID-19 infection rates than physicians and nurses.
Between 56.7 and 74.3 million US adults are at increased risk for severe COVID-19 and are either themselves an essential worker or live with one.